Literature DB >> 16904839

Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery.

Esther R Nijhuis1, Ate G J van der Zee, Bertha A in 't Hout, Jantine J Boomgaard, Joanne A de Hullu, Elisabeth Pras, Harry Hollema, Jan G Aalders, Hans W Nijman, Pax H B Willemse, Marian J E Mourits.   

Abstract

PURPOSE: The aim of this study was to evaluate efficacy of gynecologic examination under general anesthesia with cervical biopsies after (chemo) radiation for cervical cancer to identify patients with residual disease who may benefit from salvage surgery. METHODS AND MATERIALS: In a retrospective cohort study data of all cervical cancer patients with the International Federation of Gynecology and Obstetrics (FIGO) Stage IB1 to IVA treated with (chemo) radiation between 1994 and 2001 were analyzed. Patients underwent gynecologic examination under anesthesia 8 to 10 weeks after completion of treatment. Cervical biopsy samples were taken from patients judged to be operable. In case of residual cancer, salvage surgery was performed.
RESULTS: Between 1994 and 2001, 169 consecutive cervical cancer patients received primary (chemo) radiation, of whom 4 were lost to follow-up. Median age was 56 years (interquartile range [IQR], 44-71) and median follow-up was 3.5 years (IQR, 1.5-5.9). In each of 111 patients a biopsy sample was taken, of which 90 (81%) showed no residual tumor. Vital tumor cells were found in 21 of 111 patients (19%). Salvage surgery was performed in 13 of 21 (62%) patients; of these patients, 5 (38%) achieved long-term, complete remission after salvage surgery (median follow-up, 5.2 years; range, 3.9-8.8 years). All patients with residual disease who did not undergo operation (8/21) died of progressive disease. Locoregional control was more often obtained in patients who underwent operation (7 of 13) than in patients who were not selected for salvage surgery (0 of 8 patients) (p < 0.05).
CONCLUSIONS: Gynecologic examination under anesthesia 8 to 10 weeks after (chemo) radiation with cervical biopsies allows identification of those cervical cancer patients who have residual local disease, of whom a small but significant proportion may be salvaged by surgery.

Entities:  

Mesh:

Year:  2006        PMID: 16904839     DOI: 10.1016/j.ijrobp.2006.05.039

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

1.  Adjuvant hysterectomy after radiochemotherapy for locally advanced cervical cancer.

Authors:  Peter Hass; Holm Eggemann; Serban Dan Costa; Atanas Ignatov
Journal:  Strahlenther Onkol       Date:  2017-06-28       Impact factor: 3.621

2.  Patterns of care in patients with cervical cancer 2012: results of a survey among German radiotherapy departments and out-patient health care centers.

Authors:  S Marnitz; C Köhler; A Rauer; A Schneider; V Budach; A Tsunoda; M Mangler
Journal:  Strahlenther Onkol       Date:  2013-07-27       Impact factor: 3.621

3.  Aspects of Therapy for Cervical Cancer in Germany 2012 - Results from a Survey of German Gynaecological Hospitals.

Authors:  M Mangler; N Zech; A Schneider; C Köhler; S Marnitz
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-03       Impact factor: 2.915

4.  Health-related quality of life and late morbidity in concurrent chemoradiation and radiotherapy alone in patients with locally advanced cervical carcinoma.

Authors:  Maaike J Berveling; Johannes A Langendijk; Jannet C Beukema; Marian J E Mourits; Anna K L Reyners; Elisabeth Pras
Journal:  J Gynecol Oncol       Date:  2011-09-28       Impact factor: 4.401

5.  Chemoradiotherapy alone vs. chemoradiotherapy and hysterectomy for locally advanced cervical cancer: A systematic review and updated meta-analysis.

Authors:  Weijia Lu; Canxiong Lu; Zhiwu Yu; Lei Gao
Journal:  Oncol Lett       Date:  2020-12-31       Impact factor: 2.967

6.  The Prognostic Value of Tumor Size, Volume and Tumor Volume Reduction Rate During Concurrent Chemoradiotherapy in Patients With Cervical Cancer.

Authors:  Chang Sun; Shubin Wang; Wenjing Ye; RanLin Wang; Mingyu Tan; Hanyi Zhang; Jie Zhou; Minglun Li; Lichun Wei; Peng Xu; Guiquan Zhu; Jinyi Lang; Shun Lu
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

7.  Consecutive magnetic resonance imaging during brachytherapy for cervical carcinoma: predictive value of volume measurements with respect to persistent disease and prognosis.

Authors:  J E Mongula; B F M Slangen; D M J Lambregts; F Cellini; F C H Bakers; L C H W Lutgens; T Van Gorp; A J Kruse; R F P M Kruitwagen; R G H Beets-Tan
Journal:  Radiat Oncol       Date:  2015-12-08       Impact factor: 3.481

8.  Predictive criteria for MRI-based evaluation of response both during and after radiotherapy for cervical cancer.

Authors:  Jordy Mongula; Brigitte Slangen; Doenja Lambregts; Frans Bakers; Shekar Mahesh; Ludy Lutgens; Toon Van Gorp; Roy Vliegen; Roy Kruitwagen; Regina Beets-Tan
Journal:  J Contemp Brachytherapy       Date:  2016-07-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.